SELLAS Life Sciences Group (SLS) Total Non-Current Liabilities: 2011-2022
Historic Total Non-Current Liabilities for SELLAS Life Sciences Group (SLS) over the last 7 years, with Sep 2022 value amounting to $13.2 million.
- SELLAS Life Sciences Group's Total Non-Current Liabilities rose 109.76% to $13.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $13.2 million, marking a year-over-year increase of 109.76%. This contributed to the annual value of $5.6 million for FY2021, which is 58.14% down from last year.
- Per SELLAS Life Sciences Group's latest filing, its Total Non-Current Liabilities stood at $13.2 million for Q3 2022, which was up 2.02% from $13.0 million recorded in Q2 2022.
- SELLAS Life Sciences Group's Total Non-Current Liabilities' 5-year high stood at $17.1 million during Q1 2022, with a 5-year trough of $3.9 million in Q1 2020.
- Over the past 3 years, SELLAS Life Sciences Group's median Total Non-Current Liabilities value was $6.3 million (recorded in 2021), while the average stood at $8.7 million.
- In the last 5 years, SELLAS Life Sciences Group's Total Non-Current Liabilities tumbled by 58.14% in 2021 and then skyrocketed by 144.16% in 2022.
- Over the past 4 years, SELLAS Life Sciences Group's Total Non-Current Liabilities (Quarterly) stood at $5.6 million in 2019, then soared by 140.10% to $13.5 million in 2020, then tumbled by 58.14% to $5.6 million in 2021, then skyrocketed by 109.76% to $13.2 million in 2022.
- Its last three reported values are $13.2 million in Q3 2022, $13.0 million for Q2 2022, and $17.1 million during Q1 2022.